(RGA) Reinsurance of America - Overview
Stock: Life, Health, Reinsurance, Asset-Intensive, Financial
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.87% |
| Yield on Cost 5y | 3.60% |
| Yield CAGR 5y | 6.21% |
| Payout Consistency | 99.0% |
| Payout Ratio | 16.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.4% |
| Relative Tail Risk | -2.51% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -17.76 |
| Character TTM | |
|---|---|
| Beta | 0.906 |
| Beta Downside | 1.080 |
| Drawdowns 3y | |
|---|---|
| Max DD | 27.11% |
| CAGR/Max DD | 0.57 |
Description: RGA Reinsurance of America January 03, 2026
Reinsurance Group of America (RGA) delivers a broad suite of life and health reinsurance and financial solutions, ranging from term, universal, and whole-life policies to critical-illness, disability, and longevity products, as well as asset-intensive and capital-market-linked reinsurance structures. The firm also underwrites mortality, morbidity, lapse, and investment-risk layers, and it supplements its core offerings with technology platforms, consulting, and outsourcing services for insurers worldwide.
Key operating metrics highlight RGA’s strong underwriting discipline: a 2023 combined ratio of roughly 92% and net income of about $1.2 billion, yielding an ROE near 12%. The business is highly sensitive to interest-rate environments-higher rates boost investment income but can increase policy lapse rates-while demographic trends such as rising longevity risk continue to drive demand for mortality and longevity reinsurance. Geographically, RGA’s diversified presence across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa helps mitigate concentration risk.
For a deeper dive into RGA’s valuation metrics and scenario analysis, consider checking ValueRay’s analyst toolkit.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income: 719.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -4.41 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA 0.03 > 3% & CFO 4.84b > Net Income 719.5m |
| Net Debt (5.73b) to EBITDA (1.30b): 4.42 < 3 |
| Current Ratio: error (cannot be calculated; needs correct Total Current Assets and Liabilities) |
| Outstanding Shares: last quarter (66.7m) vs 12m ago -0.37% < -2% |
| Gross Margin: 13.28% > 18% (prev 0.11%; Δ 1317 % > 0.5%) |
| Asset Turnover: 12.62% > 50% (prev 18.58%; Δ -5.96% > 0%) |
| Interest Coverage Ratio: 3.84 > 6 (EBITDA TTM 1.30b / Interest Expense TTM 268.1m) |
What is the price of RGA shares?
Over the past week, the price has changed by +6.91%, over one month by +8.86%, over three months by +17.50% and over the past year by +11.42%.
Is RGA a buy, sell or hold?
- StrongBuy: 3
- Buy: 3
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RGA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 241.4 | 10.1% |
| Analysts Target Price | 241.4 | 10.1% |
| ValueRay Target Price | 248 | 13.1% |
RGA Fundamental Data Overview February 08, 2026
P/E Forward = 8.285
P/S = 0.664
P/B = 1.0056
P/EG = 1.57
Revenue TTM = 17.08b USD
EBIT TTM = 1.03b USD
EBITDA TTM = 1.30b USD
Long Term Debt = 5.73b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 5.73b USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 5.73b USD (using Total Debt 5.73b, CCE unavailable)
Enterprise Value = 20.54b USD (14.81b + Debt 5.73b - (null CCE))
Interest Coverage Ratio = 3.84 (Ebit TTM 1.03b / Interest Expense TTM 268.1m)
EV/FCF = 4.25x (Enterprise Value 20.54b / FCF TTM 4.84b)
FCF Yield = 23.56% (FCF TTM 4.84b / Enterprise Value 20.54b)
FCF Margin = 28.33% (FCF TTM 4.84b / Revenue TTM 17.08b)
Net Margin = 4.21% (Net Income TTM 719.5m / Revenue TTM 17.08b)
Gross Margin = 13.28% ((Revenue TTM 17.08b - Cost of Revenue TTM 14.81b) / Revenue TTM)
Gross Margin QoQ = none% (prev 12.38%)
Tobins Q-Ratio = 0.14 (Enterprise Value 20.54b / Total Assets 152.00b)
Interest Expense / Debt = 0.00% (Interest Expense 98.0k / Debt 5.73b)
Taxrate = 8.82% (45.0k / 510.0k)
NOPAT = 939.6m (EBIT 1.03b * (1 - 8.82%))
Current Ratio = unknown (Total Current Assets 104.20b / Total Current Liabilities none)
Debt / Equity = 0.44 (Debt 5.73b / totalStockholderEquity, two quarters ago 12.98b)
Debt / EBITDA = 4.42 (Net Debt 5.73b / EBITDA 1.30b)
Debt / FCF = 1.18 (Net Debt 5.73b / FCF TTM 4.84b)
Total Stockholder Equity = 11.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.53% (Net Income 719.5m / Total Assets 152.00b)
RoE = 6.09% (Net Income TTM 719.5m / Total Stockholder Equity 11.81b)
RoCE = 5.87% (EBIT 1.03b / Capital Employed (Equity 11.81b + L.T.Debt 5.73b))
RoIC = 5.26% (NOPAT 939.6m / Invested Capital 17.88b)
WACC = 6.68% (E(14.81b)/V(20.54b) * Re(9.26%) + D(5.73b)/V(20.54b) * Rd(0.00%) * (1-Tc(0.09)))
Discount Rate = 9.26% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 85.70% ; FCFF base≈6.51b ; Y1≈8.03b ; Y5≈13.68b
Fair Price DCF = 4721 (EV 314.81b - Net Debt 5.73b = Equity 309.08b / Shares 65.5m; r=6.68% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 50.40 | EPS CAGR: 111.1% | SUE: 2.39 | # QB: 1
Revenue Correlation: -37.85 | Revenue CAGR: -81.55% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=5.90 | Chg30d=+0.004 | Revisions Net=-1 | Analysts=7
EPS current Year (2026-12-31): EPS=25.92 | Chg30d=+0.144 | Revisions Net=-1 | Growth EPS=+14.1% | Growth Revenue=+9.9%
EPS next Year (2027-12-31): EPS=28.28 | Chg30d=+0.335 | Revisions Net=+1 | Growth EPS=+9.1% | Growth Revenue=+5.4%